BioCatalystWatch
ALXOWorkspace / ALXO / OverviewCompany library
ALX ONCOLOGY HOLDINGS INC logo

ALX ONCOLOGY HOLDINGS INC

ALX ONCOLOGY HOLDINGS INC (ALXO)

Website

Price
Market cap
Next catalystDose-escalation safety and early efficacy data in December 2026ALX2004 — ALX2004-01 · Phase 1 dataCompany release ↗
Cash

Chart & Events

Candle interval

Core Clinical

Evorpacept

CD47

PreINDP1P2P3FilingApproved
Upcoming / outlook

ALX2004

EGFR

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

ALX2004

EGFR

PreINDP1P2P3FilingApproved
Upcoming / outlook

Evorpacept

CD47

PreINDP1P2P3FilingApproved
Upcoming / outlook

Other pipelines

Evorpacept

CD47

PreINDP1P2P3FilingApproved
Evorpacept

CD47

PreINDP1P2P3FilingApproved

History / paused

Evorpacept

CD47

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Company funding outlook

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

ALXO PR & News

PR & News

ALXO SEC archive